keyword
MENU ▼
Read by QxMD icon Read
search

Metformin in obesity

keyword
https://www.readbyqxmd.com/read/28548953/from-rapalogs-to-anti-aging-formula
#1
Mikhail V Blagosklonny
Inhibitors of mTOR, including clinically available rapalogs such as rapamycin (Sirolimus) and Everolimus, are gerosuppressants, which suppress cellular senescence. Rapamycin slows aging and extends life span in a variety of species from worm to mammals. Rapalogs can prevent age-related diseases, including cancer, atherosclerosis, obesity, neurodegeneration and retinopathy and potentially rejuvenate stem cells, immunity and metabolism. Here, I further suggest how rapamycin can be combined with metformin, inhibitors of angiotensin II signaling (Losartan, Lisinopril), statins (simvastatin, atorvastatin), propranolol, aspirin and a PDE5 inhibitor...
May 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28546831/effect-of-variable-antidiabetic-treatments-strategy-on-oxidative-stress-markers-in-obese-patients-with-t2dm
#2
Abeer A ALrefai, Alsayed M Alsalamony, Sameer H Fatani, Hala F M Kamel
AIM: To evaluate the effect of different anti-diabetic treatment strategy on oxidative stress markers in patients with type 2 diabetes mellitus (T2DM). SUBJECT AND METHODS: A total of 93 patients with T2DM treated with metformin (G1 = 25), OHA (G2 = 22), OA and insulin (G3 = 26) and insulin alone (G4 = 20). In all patients, lipid profile and glycemic indices were assessed using routine laboratory tests. MDA and Oxidized LDL were assessed using commercially available ELISA kits...
2017: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/28539171/systematic-review-and-meta-analysis-of-the-effect-of-metformin-treatment-on-overall-mortality-rates-in-women-with-endometrial-cancer-and-type-2-diabetes-mellitus
#3
REVIEW
Faustino R Perez-Lopez, Vinay Pasupuleti, Ximena Gianuzzi, Gabriela Palma-Ardiles, Wendy Hernandez-Fernandez, Adrian V Hernandez
BACKGROUND: Obesity, insulin resistance and type 2 diabetes mellitus (T2DM) have been associated with endometrial cancer (EC). In this systematic review and meta-analysis we evaluated the effect of metformin on clinical outcomes in patients with EC and insulin resistance or T2DM. METHODS: Four research databases were searched for original articles published in all languages up to 30 October 2016. Outcomes of interest were overall mortality (OM), cancer-specific mortality, disease progression, and metastases...
July 2017: Maturitas
https://www.readbyqxmd.com/read/28539134/does-metformin-protect-against-osteoarthritis-an-electronic-health-record-cohort-study
#4
Lauren A Barnett, Kelvin P Jordan, John J Edwards, Danielle A van der Windt
BACKGROUND: Obesity is a major risk factor for osteoarthritis (OA) whilst there is some evidence that diabetes also increases risk. Metformin is a common oral treatment for those with diabetes. OBJECTIVE: The aim is to investigate whether metformin reduces the risk of OA. METHODS: This was a cohort study set within the Consultations in Primary Care Archive, with 3217 patients with type 2 diabetes. Patients at 13 general practices with recorded type 2 diabetes in the baseline period (2002-2003) and no prior record of OA were identified...
May 25, 2017: Primary Health Care Research & Development
https://www.readbyqxmd.com/read/28537928/differences-in-risk-factors-of-malignancy-between-men-and-women-with-type-2-diabetes-a-retrospective-case-control-study
#5
Mariusz Dąbrowski, Elektra Szymańska-Garbacz, Zofia Miszczyszyn, Tadeusz Dereziński, Leszek Czupryniak
BACKGROUND: The aim of this multicenter, retrospective, case-control study was to identify differences in risk factors of malignancy between men and women with type 2 diabetes. RESULTS: Among women the most prevalent malignancies were: breast and uterine cancers (35.6% and 14.4% respectively), while among men there were: colorectal and prostate cancers (24.5% and 13.3% respectively). In both gender metformin use was associated with lower cancer risk. Obesity and insulin treatment in dose-dependent and time-varying manner were associated with significantly increased risk of malignancy in females...
May 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28531772/diet-induced-weight-loss-and-markers-of-endothelial-dysfunction-and-inflammation-in-treated-patients-with-type-2-diabetes
#6
K A Berk, T P Oudshoorn, A J M Verhoeven, M T Mulder, A J M Roks, W A Dik, R Timman, E J G Sijbrands
BACKGROUND & AIMS: Overweight and obesity increase cardiovascular mortality in patients with type 2 diabetes (T2D). In a recent trial, however, diet-induced weight loss did not reduce the cardiovascular risk of patients with T2D, possibly due to the parallel intensive medical treatment. We investigated the effect of diet-induced weight loss on cardiovascular risk factors in overweight and obese patients with T2D, and whether this effect was influenced by the use of statins, ACE inhibitors, metformin and duration of T2D...
October 2016: Clinical Nutrition ESPEN
https://www.readbyqxmd.com/read/28531113/retrospective-evaluation-of-metformin-and-or-metformin-plus-a-new-polysaccharide-complex-in-treating-severe-hyperinsulinism-and-insulin-resistance-in-obese-children-and-adolescents-with-metabolic-syndrome
#7
Stefano Stagi, Franco Ricci, Martina Bianconi, Maria Amina Sammarco, Giovanna Municchi, Sonia Toni, Lorenzo Lenzi, Alberto Verrotti, Maurizio de Martino
Background: Pharmacological treatment of obesity and glucose-insulin metabolism disorders in children may be more difficult than in adults. Thus, we evaluate the effects of metformin in comparison with metformin plus a polysaccharide complex (Policaptil Gel Retard(®), PGR) on body weight and metabolic parameters in obese children and adolescents with metabolic syndrome (MetS). Patients and methods: We retrospectively collected 129 children and adolescents (67 girls, 62 boys; median age 12.6 years) treated for a minimum of two years with metformin and low glycemic index (LGI) diet...
May 20, 2017: Nutrients
https://www.readbyqxmd.com/read/28529546/disease-management-programs-for-patients-with-type-2-diabetes-mellitus-in-germany-a-longitudinal-population-based-descriptive-study
#8
Michael Mehring, Ewan Donnachie, Florian Cornelius Bonke, Christoph Werner, Antonius Schneider
BACKGROUND: The primary aim of the disease management program (DMP) for patients with diabetes mellitus type 2 is to improve the quality of health care and the treatment process. 12 years after its introduction in Germany, there is still no consensus as to whether DMP has been effective in reaching these goals. METHODS: A retrospective longitudinal population-based study between 2004 and 2015 were conducted to evaluate the DMP for type 2 diabetes in Bavaria using routinely collected patient medical records hold from the National Association of Statutory Health Insurance Physicians of Bavaria...
2017: Diabetology & Metabolic Syndrome
https://www.readbyqxmd.com/read/28499531/gestational-diabetes-diagnosis-classification-and-clinical-care
#9
REVIEW
Lynn R Mack, Paul G Tomich
Gestational diabetes mellitus (GDM) affects approximately 6% of pregnant women, and prevalence is increasing in parallel with the obesity epidemic. Protocols for screening/diagnosing GDM are controversial with several guidelines available. Treatment of GDM results in a reduction in the incidence of preeclampsia, shoulder dystocia, and macrosomia. If diet and lifestyle changes do not result in target glucose levels, then treatment with metformin, glyburide, or insulin should begin. It is generally recommended that pregnancies complicated by GDM do not go beyond term...
June 2017: Obstetrics and Gynecology Clinics of North America
https://www.readbyqxmd.com/read/28496346/do-we-need-to-measure-vitamin-b12-and-magnesium-in-morbidly-obese-patients-with-type-2-diabetes-mellitus
#10
Anna Wåhlén, Arvo Haenni, Hans-Erik Johansson
OBJECTIVE: We aimed to investigate the prevalence of B12 deficiency in metformin-treated, morbidly obese, type 2 diabetes mellitus (T2DM) patients, compared to morbidly obese controls, as well as to evaluate the magnesium status. DESIGN: Retrospective cross-sectional analysis of plasma vitamin B12, plasma magnesium, glucometabolic status and clinical measurements in all consecutive morbidly obese patients was conducted during 1 year. SETTING: Outpatient Clinic of Obesity Care...
2017: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
https://www.readbyqxmd.com/read/28489794/meta-analysis-of-studies-using-metformin-as-a-reducer-for-liver-cancer-risk-in-diabetic-patients
#11
Shujuan Ma, Yixiang Zheng, Yanni Xiao, Pengcheng Zhou, Hongzhuan Tan
Metformin has garnered more interest as a chemo-preventive agent given the increased liver cancer risk in diabetic patients. This work was undertaken to better understand the effect of metformin use on liver cancer risk in diabetic patients.A comprehensive literature search was performed in PubMed, Embase, BIOSIS Previews, Web of Science, and Cochrane Library through July 30, 2016. Meta-analyses were performed using Stata version 12.0, with odds ratio (ORs) and 95% confidence intervals (CIs) as effect measures...
May 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28473613/exercise-training-plus-metformin-but-not-exercise-training-alone-decreases-insulin-production-and-increases-insulin-clearance-in-adults-with-prediabetes
#12
Richard Viskochil, Steven K Malin, Jennifer M Blankenship, Barry Braun
Adding metformin to exercise does not augment the effect of training alone to boost whole-body insulin sensitivity and lower circulating insulin concentrations. While lower insulin concentrations (lower supply) following lifestyle and/or pharmacological interventions are primarily attributed to reductions in insulin secretion that match increases in peripheral insulin sensitivity (lower demand), it is unclear if exercise and/or metformin exert direct effects on insulin production, extraction or clearance. Thirty-six middle-aged, obese, sedentary adults with prediabetes were randomized to either: placebo (P), metformin (M), exercise+placebo (E+P), or exercise+metformin (E+M) for 12 weeks...
May 4, 2017: Journal of Applied Physiology
https://www.readbyqxmd.com/read/28469250/development-of-a-novel-zebrafish-model-for-type-2-diabetes-mellitus
#13
Liqing Zang, Yasuhito Shimada, Norihiro Nishimura
Obesity is a major cause of type 2 diabetes mellitus (T2DM) in mammals. We have previously established a zebrafish model of diet-induced obesity (DIO zebrafish) by overfeeding Artemia. Here we created DIO zebrafish using a different method to induce T2DM. Zebrafish were overfed a commercially available fish food using an automated feeding system. We monitored the fasting blood glucose levels in the normal-fed group (one feed/day) and overfed group (six feeds/day) over an 8-week period. The fasting blood glucose level was significantly increased in DIO zebrafish compared with that of normal-fed zebrafish...
May 3, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28465792/effects-of-intermittent-fasting-on-health-markers-in-those-with-type-2-diabetes-a-pilot-study
#14
Terra G Arnason, Matthew W Bowen, Kerry D Mansell
AIM: To determine the short-term biochemical effects and clinical tolerability of intermittent fasting (IF) in adults with type 2 diabetes mellitus (T2DM). METHODS: We describe a three-phase observational study (baseline 2 wk, intervention 2 wk, follow-up 2 wk) designed to determine the clinical, biochemical, and tolerability of IF in community-dwelling volunteer adults with T2DM. Biochemical, anthropometric, and physical activity measurements (using the Yale Physical Activity Survey) were taken at the end of each phase...
April 15, 2017: World Journal of Diabetes
https://www.readbyqxmd.com/read/28457031/prepubertal-childhood-onset-type-2-diabetes-mellitus-four-case-reports
#15
Anandakumar Amutha, Ranjit Unnikrishnan, Ranjit Mohan Anjana, Viswanathan Mohan
BACKGROUND: The prevalence of childhood onset type 2 diabetes (T2D) is increasing, but prepubertal T2D is still unusual. METHODS: We report four cases of T2D with onset at or below 10 years of age registered at a tertiary diabetes centre in southern India.T2D was diagnosed based on the absence of ketosis, good beta cell reserve as shown by the C peptide assay, absence of GAD antibodies and pancreatic calculi, and response to oral hypoglycemic agents. RESULTS: All four patients were female, obese and had acanthosis nigricans...
February 2017: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/28451430/efficacy-of-metformin-for-advanced-stage-endometrial-cancer-a-case-report
#16
Emi Sato, Kentaro Nakayama, Kohei Nakamura, Noriyoshi Ishikawa, Masako Ishikawa, Toshiko Minamoto, Tomoka Ishibashi, Satoru Kyo
The paradigm of obesity, diabetes mellitus and insulin resistance possibly plays a critical role in the pathogenesis of endometrial cancer (EC). Impaired glucose tolerance and insulin resistance may play a direct or facilitating role in the neoplastic transformation of the endometrium, whereas antidiabetic therapy, particularly with metformin, has been suggested to inhibit EC progression. We herein present the case of a patient with EC who received metformin monotherapy due to complications after undergoing surgery...
March 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28450421/the-landscape-of-histone-modifications-in-a-high-fat-diet-induced-obese-dio-mouse-model
#17
Litong Nie, Lin Shuai, Mingrui Zhu, Ping Liu, Zhi-Fu Xie, Shangwen Jiang, Hao-Wen Jiang, Jia Li, Yingming Zhao, Jing-Ya Li, Minjia Tan
Type 2 diabetes (T2D) is a major chronic healthcare concern worldwide. Emerging evidence suggests that a histone-modification-mediated epigenetic mechanism underlies T2D. Nevertheless, the dynamics of histone marks in T2D have not yet been carefully analyzed. Using a mass spectrometry-based label-free and chemical stable isotope labeling quantitative proteomic approach, we systematically profiled liver histone post-translational modifications (PTMs) in a prediabetic high-fat-diet-induced obese (DIO) mouse model...
April 27, 2017: Molecular & Cellular Proteomics: MCP
https://www.readbyqxmd.com/read/28438778/the-dual-amylin-and-calcitonin-receptor-agonist-kbp-042-works-as-adjunct-to-metformin-on-fasting-hyperglycaemia-and-hba1c-in-a-rat-model-of-type-2-diabetes
#18
Sara Toftegaard Hjuler, Sofie Gydesen, Kim Vietz Andreassen, Morten Asser Karsdal, Kim Henriksen
KBP-042 is a dual amylin and calcitonin receptor agonist which increases glucose tolerance and insulin action, and reduces body weight in rat models of obesity and pre-diabetes. The objective of the present study was to 1) Evaluate KBP-042 as a treatment of late stage type 2 diabetes in a rat model and 2) Assess the value of adding KBP-042 to the standard of care, metformin, in order to consider KBP-042 as a relevant drug for treating patients with type 2 diabetes. Two studies were included: an intervention and a prevention study...
April 24, 2017: Journal of Pharmacology and Experimental Therapeutics
https://www.readbyqxmd.com/read/28436599/metformin-as-targeted-treatment-in-fragile-x-syndrome
#19
Angel Belle C Dy, Flora Tassone, Marwa Eldeeb, María J Salcedo-Arellano, Nicole Tartaglia, Randi Hagerman
Individuals with Fragile X Syndrome (FXS) may be affected by several comorbid conditions, both behavioral and medical. Growth findings suggest that they are at an increased risk for obesity and overeating. The Prader-Willi phenotype (PWP) of FXS occurs in less than 10% of patients but it is associated with severe hyperphagia, lack of satiation and morbid obesity. Metformin is a drug used in individuals with high risk for diabetes type 2, obesity or impaired glucose tolerance. It has had a strong safety profile in children and adults with type 2 diabetes and obesity...
April 24, 2017: Clinical Genetics
https://www.readbyqxmd.com/read/28432082/effect-of-oral-contraceptives-and-or-metformin-on-glp-1-secretion-and-reactive-hypoglycemia-in-pcos
#20
Dorte Glintborg, Hanne Mumm, Jens Juul Holst, Marianne Andersen
CONTEXT: Insulin resistance in polycystic ovary syndrome (PCOS) may increase the risk of reactive hypoglycaemia (RH) and decrease glucagon-like peptide-1 (GLP-1) secretion. The possible effects of treatment with oral contraceptives (OCP) and/or metformin on GLP-1 secretion and risk of RH in PCOS is undetermined. SETTING: Outpatient clinic. PATIENTS AND INTERVENTIONS: Randomized, controlled clinical trial. Ninety women with PCOS were randomized to 12 month treatment with OCP (150 mg desogestrel+30 microgram ethinylestradiol), metformin (2 g/day), or metformin +OCP...
April 21, 2017: Endocrine Connections
keyword
keyword
17082
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"